Revelation Biosciences, Inc. announced a new target indication for its proprietary Gemini formulation: the prevention of infection in severe burn patients requiring hospitalization. This new program, designated GEM-PBI, represents a strategic expansion of the Gemini platform. The use of Gemini for this indication is part of a patent family previously licensed from Vanderbilt University.
Preclinical research conducted by the Vanderbilt team demonstrated that Gemini treatment post-burn significantly reduces the severity and duration of pseudomonas lung infection. The studies also showed a reduced overall level of inflammation in a preclinical model. These findings support the potential efficacy of Gemini in this new indication.
CEO James Rolke stated that the GEM-PBI program may offer several regulatory, development, and funding opportunities for the company. Invasive infection, including sepsis, is the primary cause of death after burn injury, accounting for an estimated 51% of deaths, highlighting a significant unmet medical need. Currently, no approved treatments exist for preventing systemic infection in burn patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.